<DOC>
	<DOCNO>NCT00541567</DOCNO>
	<brief_summary>This placebo-controlled , randomize , double-blind , parallel arm , multicenter , dose-ranging phase IIb trial ass glycemic weight loss efficacy safety BMS-646256 overweight obese patient type 2 diabetes treat diet exercise half-maximal great metformin ( ≥1500mg/day ) sulfonylurea monotherapy ( stable dose least three month ) , remain inadequately control ( HbA1c &gt; 7 % HbA1c &lt; 10 % ) .</brief_summary>
	<brief_title>BMS-646256 Obese Overweight Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Ibipinabant</mesh_term>
	<criteria>Patients age 1870 year BMI ≥27 type 2 diabetes treat diet exercise half maximal great metformin sulfonylurea monotherapy ( stable dose least three month ) , remain inadequately control ( HbA1c &gt; 7 % HbA1c &lt; 10 % ) . Pregnancy Antidiabetic medication baseline metformin sulfonylurea monotherapy History myocardial infarction prior six months/ History heart failure define New York Heart Association Functional Class I , II , III IV/ History symptomatic arrhythmia Active hepatic disease/ Any document muscle disease History multiple sclerosis/ Baseline history tremor , ataxia , anxiety dizziness Seizures within last year , stroke , transient ischemic attack/ Known history schizophrenia , dementia , bipolar disorder define DSM IV criterion . Currently depressed subject CESD score great equal 16 screen visit baseline ( Day 1 ) / History suicide attempt ideation Previous history surgical procedure weight loss ( e.g . stomach stapling , bypass ) / Weight loss great 5 kg prior 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Wheight management T2D</keyword>
</DOC>